Sanara MedTech Inc. (NASDAQ:SMTI – Get Free Report) has been assigned an average recommendation of “Reduce” from the five ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $35.00.
Several equities analysts recently weighed in on SMTI shares. Freedom Capital downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Sanara MedTech in a report on Wednesday, November 4th. HC Wainwright cut Sanara MedTech from a “buy” rating to a “neutral” rating and lowered their price target for the company from $36.00 to $35.00 in a report on Thursday, July 30th. Wall Street Zen downgraded shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Lake Street Capital downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 price objective for the company. in a research note on Thursday, July 30th.
View Our Latest Stock Analysis on SMTI
Sanara MedTech Trading Down 0.6%
Shares of NASDAQ:SMTI traded down $0.19 during midday trading on Friday, reaching $32.35. The company’s stock had a trading volume of 24,981 shares, compared to its average volume of 101,015. The firm has a market cap of $297.30 million, a price-to-earnings ratio of -92.43 and a beta of 1.23. The company has a quick ratio of 2.30, a current ratio of 2.58 and a debt-to-equity ratio of 5.86. Sanara MedTech has a 1 year low of $16.05 and a 1 year high of $35.52. The business has a 50 day moving average price of $33.98 and a 200 day moving average price of $26.00.
Institutional Investors Weigh In On Sanara MedTech
Institutional investors have recently bought and sold shares of the stock. Deutsche Bank AG acquired a new position in Sanara MedTech during the second quarter worth approximately $98,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Sanara MedTech in the 3rd quarter valued at $249,000. Carlson Capital L.P. acquired a new position in shares of Sanara MedTech in the 3rd quarter valued at $467,000. Bank of America Corp DE acquired a new position in shares of Sanara MedTech in the 2nd quarter valued at $376,000. Finally, Jump Financial LLC purchased a new stake in shares of Sanara MedTech during the 3rd quarter valued at $597,000. 8.10% of the stock is currently owned by hedge funds and other institutional investors.
Sanara MedTech Company Profile
Sanara MedTech, Inc. develops, markets and distributes medical products for wound care, surgical tissue repair and related applications. Its offerings are intended for use by healthcare professionals treating acute and chronic wounds and supporting tissue healing. The company’s portfolio includes CellerateRX® collagen-based products and BIAK?S® antimicrobial products, along with other solutions for wound and surgical care. Sanara sells its products to healthcare providers and through distribution channels.
Recommended Stories
- Five stocks we like better than Sanara MedTech
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
